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Introduction
The number of cardiac implantable electronic device (CIED) implant-
ations has increased over recent years1,2 as a result of population
growth, increasing life expectancy, adoption of guidelines, and better
access to healthcare. Transvenous lead extraction (TLE), as a part of
an overall lead management strategy, has also been increasing, not
only as a consequence of this growth, but also because of increasing
rates of infection,3 lead failure, awareness of indications for lead man-
agement, and development of extraction tools. Clinical research is
essential for understanding efficacy and risks of TLE, which has im-
portant implications regarding decision-making and therapeutic strat-
egies in patients who are candidates for this procedure. Data on TLE
have mainly come from retrospective series, with variable reporting
of endpoints. Recently, the ELECTRa registry conducted by the
European Heart Rhythm Association (EHRA), has reported the larg-
est prospective experience on lead extraction published to date in
3555 patients recruited from 19 European countries.4 There remain
unresolved issues, which is a strong incentive for conducting further
specifically-designed clinical trials to answer important questions in
this area. In addition to clinical studies, national registries are poten-
tially useful for evaluating epidemiology of TLE as well as for quality
control and understanding resource implications. Standardization of
definitions and reporting of parameters are paramount in order to
analyse, compare, and pool data for scientific purposes. Expert con-
sensus statements on lead extraction have been published by the
Heart Rhythm Society (HRS) in 20095 and 2017,6 and by EHRA in
2012.7 Experience from the ELECTRa registry has been valuable for
identifying challenges faced with conducting scientific studies in this
field, and provides a framework for future endeavours.
This writing group has been commissioned by EHRA to provide
recommendations for designing scientific studies, reports and regis-
tries relating to lead extraction.
Indications for lead extraction
In order to clarify the indications for lead extraction the following
definitions are proposed (see Table 1).
Infection
This was the most frequent indication for TLE in the ELECTRa regis-
try amounting to 52.8% (of which approximately two-thirds were
local infections).4 Several entities exist, which should be specified.
Isolated pocket infection
This is defined as an infection limited to the generator pocket or along
the lead course. It is clinically associated with local signs of inflamma-
tion, including erythema, warmth, fluctuance, wound dehiscence, ten-
derness, or purulent drainage, with negative blood cultures.8–10 This
entity should be differentiated from superficial incisional Infection, which
involves only skin and subcutaneous tissue without communication
with the pocket (and may not require lead extraction).
Isolated pocket erosion
This is a chronic process whereby the device and/or lead(s) are
exposed through the skin, with or without local signs of infection
(the device should however be considered infected, whatever the
mechanism for erosion). Very often the erosion is preceded by the
adherence of the skin on the device with a concomitant browning
and thinning of the skin. Erosion is usually indicative of infection.
Blood cultures are negative, and some of these patients are asymp-
tomatic, while others complain of local pain.
Bacteraemia
In presence of positive blood cultures with or without systemic infec-
tion symptoms and signs.
Pocket infection with lead/valvular endocarditis
Local signs of pocket infection and positive blood cultures and lead
or valvular vegetation(s). The 2015 European Society of Cardiology
(ESC) modified Duke Criteria8 have been used to define endocarditis.
It should be noted that these criteria are used to define valvular endo-
carditis. For CIED-related endocarditis, additional criteria might be
.................................................................................................
Table 1 CIED-related infection types
Clinical scenarios Infection
types
Definitions
Superficial incisional
infection
Superficial
local
Involves only skin and subcutane-
ous tissue
Isolated pocket
infection
Local Clinically associated with local
signs of inflammation at the
generator pocket or along the
lead course, including ery-
thema, warmth, fluctuance,
wound dehiscence, tenderness,
or purulent drainage, with
negative blood cultures8–10
Isolated pocket
erosion
Local Device and/or lead(s) are
exposed through the skin (the
device should however, be
considered infected, whatever
the mechanism for erosion)
Bacteraemia Systemic Positive blood cultures with or
without systemic infection
symptoms and signs
Pocket infection
(open or closed)
with bacteraemia
Systemic Local signs of pocket infection
and positive blood cultures,
without lead or valvular
vegetation(s)
CIED-related endo-
carditis without
pocket infection
Systemic Bacteraemia and lead or valvular
vegetation(s), without local
signs of pocket infection
Pocket infection with
lead/valvular
endocarditis
Systemic Local signs of pocket infection
and positive blood cultures and
lead or valvular vegetation(s)
Occult bacteraemia
with probable
CIED infection
Systemic Bacteraemia without an alterna-
tive source
CIED, cardiac implantable electronic device.
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considered, such as positive cultures of the extracted lead in case of
negative blood cultures, presence of lead vegetations, and abnormal
metabolic activity around the CIED generator and/or leads detected
by 18F-fluorodeoxyglucose (FDG) positron emission tomography
(PET)/computed tomography (CT) or radiolabelled leucocytes
single-photon-emission computed tomography/CT.
Pocket infection with bacteraemia
Local signs of pocket infection and positive blood cultures, without
lead or valvular vegetation(s).
Cardiac implantable electronic device-related
endocarditis without pocket infection
Bacteraemia with or without lead or valvular vegetation(s), and with-
out local signs of pocket infection.
Occult bacteraemia with a presumable cardiac
implantable electronic device infection
Bacteraemia without an obvious source other than the CIED. After
extraction, disappearance of bacteraemia is expected.
Lead dysfunction
In case of lead dysfunction, there is the option of abandoning the lead
or extracting it (e.g. to reduce intravascular lead burden or regain ac-
cess in the presence of venous occlusion). Lead dysfunction was the
second most frequent reason for lead extraction in the ELECTRa
registry, amounting to 38.1% of cases.4 Causes for lead dysfunction
may be lead fracture or insulation failure resulting in issues with lead
impedance, sensing or capture. In some cases, the electrical param-
eters may still be normal, but the integrity of the lead is clearly com-
promised (e.g. inside out cable externalization of Riata leads,
radiological evidence of subclavian crush etc.).
Abandoned functional leads
There are a variety of situations where a functional lead may no lon-
ger be required, with the option of either abandoning or extracting
the lead. Examples are upgrades from a pacemaker to an implantable
cardioverter-defibrillator (ICD), downgrading from dual- to single-
chamber systems, lead recall with prophylactic revision, system re-
location for radiotherapy, lack of device indication etc. These aban-
doned leads may be extracted to reduce the intravascular lead
burden in order to avoid future issues (see Table 2).
Lead-related complications
Leads may be functional but cause complications for which extraction
may be indicated (e.g. thromboembolic events, superior vena cava
syndrome, arrhythmias, perforation, lead-lead interaction etc.).
If stenting is planned for treating stenosis in a vein with a transvenous
lead, extraction is usually performed to avoid entrapment of the lead.
Venous access issues
Up to 25% of patients with transvenous leads develop some degree
of stenosis,11 which may later hinder additional lead implantation (e.g.
in case of upgrades). There are a number of different management
strategies,12 which include tunnelling a contra-lateral lead across the
chest, venoplasty, or lead extraction to provide a channel through
which new leads can be implanted.
Access to magnetic resonance imaging
There is evidence that magnetic resonance imaging (MRI) can be
safely performed in patients implanted with non-conditional CIEDs,
but abandoned or dysfunctional leads are considered to be contra-
indications (even if an MRI-conditional device is implanted).13
Therefore, extraction of these leads may be performed in selected
cases, with appropriate assessment of the risk and benefits of the lead
extraction procedure, in order to allow access to MRI, when no
other diagnostic alternatives to MRI are available.
Chronic pain
Some patients may have severe chronic pain attributed to lead inser-
tion (e.g. due to a periosteal reaction), for which lead extraction may
be performed. It is important to recognize that chronic pain may be a
sign of an infection.
Other indications
A number of other rare indications for lead extraction exist, such as
prophylactic extraction of leads that due to their design or their
.................................................................................................
Table 2 Definitions of terms for non-infected leads
Non infected
leads
Definitions
Lead function Any lead function, including pacing, sensing,
and/or defibrillation
Lead failure Loss of any lead function
Non-functional
lead
Lead not usable for pacing and/or defibrillation
due to loss of functional integrity
Abandoned
lead
Lead left in place in the heart and not con-
nected to a CIED. It may be functional or
non-functional. ‘Redundant’ lead is some-
times used to describe an abandoned lead
Recall Firm’s removal or correction of a marketed
product that the US Food and Drug
Administration (FDA) or the European
Medicines Agency (EMA) consider to be in
violation of the laws it administers and
against, which the agency would initiate legal
action. Recall does not include a market
withdrawal or a stock recovery
Class 1 Dangerous or defective products with reason-
able probability of causing serious health
problems or death (e.g. short circuit without
warning)
Class 2 Products that might cause a temporary health
problem, or pose a slight threat of a serious
nature (e.g. premature battery depletion)
Class 3 Products that are unlikely to cause any adverse
health reaction, but that violate FDA or EMA
labelling or manufacturing regulations
CIED, cardiac implantable electronic device.
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failure pose a potential future threat to the patient if left in place e.g.
Accufix leads (Telectronics).
Approaches, tools and techniques
Lead removal often includes a wide spectrum of tools and tech-
niques, ranging from simple manual traction to multiple procedures
and combined approaches (see Table 3).
Approaches
Most lead extractions are performed using a percutaneous approach
as it is less invasive. In specific situations (e.g. high-risk procedures or
in case of very large vegetations), an open extraction with sternot-
omy and cardiopulmonary bypass may be preferred. Some centres
perform hybrid approaches that combine percutaneous extraction
with minimally invasive surgery or thoracoscopy. The various
approaches for percutaneous TLE are detailed below.
Superior approach
Most lead extraction procedures begin via the identical route of lead
implantation, also known as venous entry or implant vein approaches.
If the venous entry approach fails, or in the presence of free-floating
leads, an internal jugular venous approach can be used, combining su-
perior and femoral accesses.14
Inferior/femoral approach
Extraction may be performed with femoral venous access as a pri-
mary strategy or as a bailout procedure, using specialized tools.15
Tools and techniques
When reporting data for lead extraction procedures, it is important
to be specific regarding the tools and techniques used, as these will
have a direct impact on outcome and also on costs. Often, a ‘step-
wise’ approach is used whereby the operator transitions from simple
to more complex strategies. Therefore, different tools and tech-
niques may be used during a procedure, even for the same lead. In
case of a stepwise approach, it is useful to report the sequence of
techniques, which were employed for a given lead.
Simple traction
Applying mild pulling force without the use of specialized tools (other
than a standard stylet) was used in 27% of patients in the ELECTRa
registry,4 and may be effective for leads with a short dwell time (i.e.
time since implant <1–2 years).
Locking stylets
These are designed to improve tensile strength to facilitate traction
and to stabilize leads. They may be used alone or in combination with
other tools such as sheaths.
Mechanical non-powered telescoping sheaths
These sheaths are designed for blunt dissection of fibrotic binding
sites, using simple manual pushing/rotational force. They are most
often composed of polypropylene, but metallic or Teflon (PTFE)
sheaths are also available. They may be used alone or with handles
that facilitate rotation, and most often with a locking stylet.
Powered sheaths
When reporting use of powered sheaths, it is important to specify
which type of tool was used, as their mechanism, efficacy and risk
profiles may differ. They are used in conjunction with a locking sty-
let inserted into the lead, which builds a rail upon which the device
is advanced. Rotational mechanical sheaths are currently hand pow-
ered and have a threaded tip which dissects adherent tissue.16
Electrosurgical sheaths use radiofrequency energy to dissect fibrous
tissue but are now seldom used. Laser sheaths use laser energy
delivered circumferentially along the tip of the sheath.17 As additional
tools become available this list should be expanded accordingly.
Snares
These are most often deployed via a femoral approach, and may con-
sist of a single or double15 loop, which can be used for grasping free-
floating lead extremities or the lead body (double loop design).
.................................................................................................
Table 3 Definition of LE approaches, techniques and
tools
Type Definitions
Approach Defined according to vein used to re-
move the lead
Transvenous Percutaneous (closed) lead removal
performed through a central vein
(subclavian, jugular, and femoral)
Superior approach Lead removed above the diaphragm
Venous entry site Lead removed using the implantation
venous entry site (right or left sub-
clavian, axillary, cephalic, and jugular
vein)
Transjugular Lead removed using the right internal
jugular vein
Inferior approach Lead removed below the diaphragm
(right or left femoral vein)
Surgical Surgical (open) lead removal.
Includes standard sternotomy,
minithoracotomy, or hybrid approach
Tools and techniques Defined according to the tool used
Sheath
Non-powered No additional energy (i.e. simple
mechanical sheath)
Powered Additional energy (laser, assisted
rotational mechanical, and RFA
sheath)
Stylet Standard, locking
Snares
Basket
Deflectable wires
Lead extenders
Compression coils
Occlusion balloons
LE, lead extraction; RFA, radiofrequency ablation.
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Baskets
These devices are usually introduced via a femoral approach to grasp
free-floating lead extremities, but are seldom used today.
Lead extenders
These wires are used for grasping conductor cables or lumenless
leads in order to be able to use an extraction sheath.
Compression coils
These tools allow secure binding of locking stylets and the proximal
components of the lead to facilitate extraction.18
Occlusion balloons
In case of a vascular tear, these highly compliant balloons are filled
with diluted contrast agents to stem bleeding while awaiting surgical
bailout.19
Other tools
Tools that are dedicated to other procedures may sometimes be
used for lead extraction (e.g. for grasping leads), such as pigtail cath-
eters, deflectable wires, deflectable catheters, bioptomes, deflectable
sheaths etc.
It is recommended to report the size of the tools used, as these
may impact complications (e.g. bleeding at the venous entry site, col-
lateral damage, etc.). However, it is important to realize that tool size
may be labelled differently (e.g. mechanical sheath size usually refers
to internal diameters, whereas laser sheath size refers to external
diameter), and that use of outer sheaths will also impact tool size.
Procedures and outcomes
To interpret studies, whether prospective randomized trials or retro-
spective studies, there must be clear and consistent definitions. Since
many complications may occur after the patient leaves the proced-
ural venue, appropriate follow-up should be performed. In addition,
true informed consent requires each operator to know their own
volumes and outcomes. This requires tracking outcomes and being
able to report them in a comparable way. Definitions of what consti-
tutes a lead extraction, procedural outcomes and complications have
been well delineated in the 2009 and 2017 HRS expert consensus
documents on TLE,5,6 and used in the recently-reported ELECTRa
Registry.4 It will be the goal of this section to keep with existing defin-
itions, to reinforce the importance of consistency.
Definitions of procedures
A review of the literature demonstrates that the definition of lead ex-
traction has varied widely, which makes subsequent reporting of the
utility, safety and efficacy of lead extraction procedures difficult to
compare. The removal of a 3-month old lead is clearly different from
removing a 20-year old lead. To address this, the 2009 HRS
Consensus document5 created clear definitions for what is, and is not
a lead extraction procedure, which have been adopted in the 2017
HRS consensus6 and also in this document. When classifying a pro-
cedure the following definitions should be employed.
Lead removal
Removal of a pacing lead or defibrillator lead using any technique.
This entity includes removal of subcutaneous ICD leads.
Lead explant
A lead removal using simple traction techniques (no locking stylets,
telescoping sheaths, or femoral extraction tools) and all removed
leads were implanted within 1 year.
Lead extraction
Intervention with removal of at least one lead that has been im-
planted for more than 1 year, or a lead regardless of duration of im-
plant requiring the assistance of specialized equipment that is not
included as part of the typical implant package, and/or removal of a
lead from a route other than the implant vein. Percutaneous removal
of leadless pacemakers may be considered as extraction procedures.
Definition of success
For scientific purposes, it is important to distinguish success of the
procedure as a whole, as well as to gather data on success of extrac-
tion of individual leads (e.g. in order to compare results for atrial, ven-
tricular, coronary sinus leads, and for defibrillator vs. pacing leads).
The definition of success will depend very much upon follow-up, and
can only be assumed in case the follow-up is limited. In case of in-
fected leads, a complete CIED removal is warranted, even if a <4 cm
remnant may be accepted according to consensus of opinion. In case
of non-infected leads, clinical success may be obtained despite per-
sistence of residual lead tip on imaging. A list of definitions regarding
lead- and procedure-related outcome is reported in Table 4.
Complete procedural success
Removal of all targeted leads and material, with the absence of any
permanently disabling complication or procedure-related death.
Complete procedural success rate
Procedures where there is complete success, divided by the total
number of procedures.
Clinical procedural success
Retention of a small portion of a lead that does not negatively impact
the outcome goals of the procedure. This may be the tip or a small
part (<4 cm) of the lead (conductor coil, insulation, or the two com-
bined) when the residual part does not increase the risk of perfor-
ation, embolic events, perpetuation of infection, or cause any
undesired outcome. Absence of any permanently disabling complica-
tion or procedure-related death.
Procedural clinical success rate
Procedures where there is clinical success divided by the total num-
ber of extractions.
Procedural failure
Inability to achieve either complete procedural or clinical success, or
the development of any permanently disabling complication or
procedural-related death.
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Procedural failure rate
Extraction procedures that failed divided by the total number of
procedures.
Complete lead removal
Lead explant or extraction with removal of all targeted lead material.
Incomplete lead removal
Lead explant or extraction where part of the lead remains in the pa-
tient’s body (vascular or extra-vascular).
Definition of complications
Attribution of complications is more complex as patients may also be
undergoing additional procedures at the time of extraction, such as
reimplantation (e.g. was the pocket haematoma post-procedure due
to the extraction or the reimplantation?). In addition, pre-existing
conditions can greatly impact outcomes (e.g. did the patient die
3 days post-procedure as a complication of the extraction or due to
the overwhelming sepsis that was the indication for the extraction?).
It is important that outcomes be reported as objectively as possible
to avoid bias. The attribution of the complication is less important to
the patient than the fact the complication occurred. All complications
must be documented and traced (a list of possible complications is
shown in Table 5). Again, clear definitions help to remove subjective
analysis and allow for a clearer understanding of the risks of the pro-
cedure. As per the 2009 and 2017 Consensus documents,5,6 compli-
cations are defined by their time in relation to the procedure and
their severity.
Timing
Intra-procedural complications
Any event related to the performance of a procedure that occurs or
becomes evident from the time patient enters the operating room
until the patient leaves the operating room. This includes complica-
tions related to the preparation of the patient, the delivery of anaes-
thesia, and opening and closing the incision.
Early post-procedure complications
Any event related to the procedure that occurs or becomes evident
within 30 days following the intra-procedural period.
Late post-procedure complications
Any event related to the procedure that occurs or becomes evident
after 30 days following the intra-procedural period and during the
first year.
....................................................................................................................................................................................................................
Table 4 Definitions for extraction procedures and outcomes
Terms Definitions
Lead removal procedure Removal of a pacing or ICD lead using any technique
Lead explant Lead removal using simple traction techniques (no locking stylets, telescoping sheaths, or femoral ex-
traction tools) and all removed leads were implanted since <1 year
Lead extraction Intervention with removal of at least one lead that has been implanted for more than 1 year or a lead re-
gardless of duration of implant requiring the assistance of specialized equipment that is not included
as part of the of the typical implant package and/or removal of a lead from a route other than the im-
plant vein
Definition of success
Lead-related
Complete lead removal Lead explant or extraction with removal of all targeted lead material
Incomplete lead removal Lead explant or extraction where part of the lead remains in the patient’s body (vascular or extra-
vascular)
Procedure (patient)-related
Complete procedural success Removal of all targeted leads and material, with the absence of any permanently disabling complication
or procedure-related death
Complete procedural success rate Procedures where there is complete success, divided by the total number of procedures
Clinical procedural success Retention of a small portion of a lead that does not negatively impact the outcome goals of the proced-
ure. This may be the tip or a small part (<4 cm) of the lead (conductor coil, insulation, or the two
combined) when the residual part does not increase the risk of perforation, embolic events, perpetu-
ation of infection, or cause any undesired outcome. Absence of any permanently disabling complica-
tion or procedure-related death
Clinical procedural success rate Procedures where there is clinical success divided by the total number of extractions
Procedural failure Inability to achieve either complete procedural or clinical success, or the development of any perman-
ently disabling complication or procedural-related death
Procedural failure rate Extraction procedures that failed divided by the total number of procedures
ICD, implantable cardioverter-defibrillator.
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Severity
Complications are divided into major or minor groupings with obser-
vations on severity and reversibility. All unexpected occurrences
must be documented and tracked. This allows accurate reporting and
the ability to monitor quality and subsequent outcomes. An increased
incidence in a specific complication must be investigated and a ‘root
cause’ analysis performed. Previously unrecognized complications
can be identified, only if all untoward events are tracked.
Major complications/serious adverse events
Any of the outcomes related to the procedure, which is life-
threatening or results in death (cardiac or non-cardiac). In addition,
any unexpected event that causes persistent or significant disability,
requires inpatient hospitalization or prolongation of existing hospital-
ization, or any event that requires significant surgical intervention to
prevent any of the outcomes listed above.
Minor complications
Any undesired event related to the procedure that requires medical
intervention or minor procedural intervention to remedy, and does
not limit persistently or significantly the patient’s function, nor does it
threaten life or cause death.
Duration of follow-up
Procedural outcomes are as standard reported for a 30-day period.
This helps track acute complications and outcomes directly related
to the procedure, and should be the minimum follow-up duration.
Ideally outcomes should be tracked for a much longer period (e.g.
1 year). This would allow for a better understanding of the outcomes
related to the underlying indication for extraction (e.g. recurrence of
infection) and if an extraction approach has long term sequelae. For
example, patients undergoing extraction for a systemic-related de-
vice infection have close to a 25% 1 year mortality, despite successful
extraction. In addition, preliminary data suggests early extraction for
infection improves 1 year survival.
Database parameters
The quality of any scientific study or registry is principally determined
by the quality of the data. As with any project, there is a trade-off be-
tween volume/detail of information to be captured, and practicality
for the investigators having to enter the data (which will determine
compliance). Every effort should be made to standardized items with
tick boxes and scroll menus and avoid any free text.
Different database platforms are available. One such platform is
Research Electronic Data Capture (https://projectredcap.org/), initi-
ated at Vanderbilt University and developed by a multi-institutional
consortium. This is a free, secure web-based application that can be
used to create centre-specific databases. An advantage of this applica-
tion is that it allows multisite access, and data can be shared between
several institutions.
A list of parameters are detailed below (the necessity of capturing
individual parameters will depend upon the purpose of the study/
registry), and an example of a case report form is available on the
Supplementary material online, Appendix.
Pre-procedure
(1) Patient
• Demographics (age, height, weight, medication etc.).
• Cardiac and non-cardiac conditions (e.g. prior open heart
surgery, left ventricular ejection fraction, New York Heart
Association (NYHA) class, presence of ischemic heart dis-
ease, atrial fibrillation, renal insufficiency, diabetes, cerebro-
vascular accident etc.) as these may affect procedural
outcome.20
• Indication for the CIED.
• Pacemaker dependence.
• Indication for extraction.
• Antibiotic information should be recorded (type, duration,
timing).
(2) Device and leads
• Number of leads.
• Type of device and all leads. The lead consists of the body,
conductors, electrodes, insulation, fixation mechanisms, and
each of these components can influence the extractability of
the lead.21 It is therefore important that these data are avail-
able for analysis. The precise characteristics of an extracted
lead may be retrieved if the model is entered in the database
(ideally using pull-down lists to avoid errors in data entry, for
facilitating analysis, and automatically linking each lead model
to the specific characteristics). As an alternative, the main
characteristics (e.g. active- vs. passive-fixation, single- vs. dual-
coil ICD leads, subcutaneous leads, epicardial leads, or
patches etc.) may be captured manually for each lead. The
.................................................................................................
Table 5 Complications (table from reference6)
Incidence%
Major 0.19–1.80
Death 0.19–1.20
Cardiac avulsion 0.19–0.96
Vascular laceration 0.16–0.41
Respiratory arrest 0.20
Cerebrovascular accident 0.07–0.08
Pericardial effusion requiring intervention 0.23–0.59
Haemothorax requiring intervention 0.07–0.20
Cardiac arrest 0.07
Thromboembolism requiring intervention 0.07
Flail tricuspid valve leaflet requiring intervention 0.03
Massive pulmonary embolism 0.08
Minor 0.06–6.20
Pericardial effusion without intervention 0.07–0.16
Haematoma requiring evacuation 0.90–1.60
Venous thrombosis requiring medical intervention 0.10–0.21
Vascular repair at venous entry site 0.07–0.13
Migrated lead fragment without sequelae 0.20
Bleeding requiring blood transfusion 0.08–1.00
AV fistula requiring intervention 0.16
Pneumothorax requiring chest tube 1.10
Worsening tricuspid valve function 0.02–0.59
Pulmonary embolism 0.24–0.59
AV, arteriovenous.
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manufacturer and model for the device and leads should be
noted.
• Duration of implant of all leads—as procedural success and
complications are related to this factor.
• Position of leads (right atrial appendage/lateral wall/septum;
right ventricular apex/septum/outflow tract; coronary sinus
tributary etc.).
• Presence of problem of leads including externalized con-
ductors, fractured leads, lead fragments etc.
• Previous attempts at extraction (and the methods used).
(3) Investigations
• Imaging findings: chest X-ray (analysis of leads, presence of
calcifications), echocardiography (cardiac function, tricuspid
regurgitation, intra-cardiac shunt, vegetations, pre-existing
pericardial fluid etc.), contrast venography/CT (vein stenosis/
occlusion, extravascular lead segments etc.), PET/CT etc.
• Blood tests: renal function, coagulation tests, haemoglobin,
platelet count etc. (as these parameters may affect outcome,
and in order to compare with post-procedure values), results
of blood cultures (if infection is suspected) and pathogens
identified.
Intra-procedure
(1) Date of procedure.
(2) Emergent or scheduled procedure.
(3) Location: operating room, cath/electrophysiology (EP) lab or hy-
brid lab.
(4) Anaesthesia (local or general).
(5) Personnel (in particular whether a cardiac surgeon is scrubbed in
or standing by, operator experience, centre annual volume).
(6) Intra-operative imaging (type of fluoroscopy, transoesophageal
and intra-cardiac echocardiography, venography etc.) and their
findings (presence of ‘ghosts’, tricuspid regurgitation, pericardial ef-
fusion, intra-cardiac shunt etc.).
(7) Approaches.
(8) Specialized tools used (optionally, in which order for each lead).
(9) Use of accessory tools (temporary pacing wire, guidewire in the
superior vena cava etc.).
(10) Additional interventions performed during the procedure (e.g.
pocket debridement, venoplasty, lead abandonment with or with-
out transection of the lead etc.).
(11) Success of extraction for each lead: complete, partial (<4 cm re-
mains in situ), failure (>4 cm remains in situ).
(12) Reimplantation (if applicable): access site, type of device (as this
may affect total procedure and fluoroscopy durations).
(13) Intra-operative complications (tachyarrhythmias, atrioventricular
block, pericardial bleeding etc.) and their management. If known,
the location of vascular tears or cardiac perforation should be
mentioned, as they have an impact on outcome.
(14) Duration: skin-to-skin, fluoroscopy (including dose).
Post-procedure
(1) Monitoring performed.
(2) Blood tests.
(3) Post-extraction rhythm management requirements (e.g. wearable
cardioverter defibrillator, temporary pacing etc.).
(4) Reimplantation (date, type of device, access site).
(5) Date of discharge.
(6) Post-operative complications (including date and management).
(7) Reinfection (type and management).
(8) Duration of follow-up.
Gaps in evidence
There are numerous gaps in evidence in the topic of lead extraction.
Some of the gaps are listed below.
Management of infected leads
Although in case of infected devices a complete removal is recom-
mended, the following points have to be addressed:
(1) Defining the role of additional diagnostic tools (PET, intra-cardiac
echocardiography) in patients with occult infections.
(2) Clinical effectiveness of different antibiotic strategies (type of antibi-
otic and duration of treatment) and their cost-effectiveness.
(3) Develop a scoring system to assess the risk of serious complications
associated with percutaneous removal that will identify a subset of
patients for whom an open surgical approach for CIED extraction is
recommended).20
(4) Determine the safety of 1-stage contralateral device replacement
compared with 1-stage epicardial or delayed device replacement as
management schemes in local and systemic infection.
(5) Timing of reimplantation, duration of antibiotics.
(6) Evaluate whether open heart surgery is needed in patients with a
prosthetic valve and lead/valvular endocarditis, but without an
hemodynamic or other valve-related indication for open heart sur-
gery (e.g. valve dysfunction). Also what is a safe vegetation size to be
extracted by TLE, versus open surgical removal.
Management of abandoned and recalled
leads
Abandoned or recalled pacemaker and ICD leads create a challenging
decision-making process when considering extraction. The main
issues are around clearly defining: (i) the risk associated with lead
abandonment and (ii) whether the potential benefit of lead extraction
outweighs the risk of the procedure. In an analysis of the National
Cardiovascular Data Registry (NCDR) ICD Registry, patients
undergoing removal of an unused or malfunctioning ICD lead had
slightly higher in-hospital complications and deaths than those with a
lead abandonment strategy.22 There are few data on the lead burden
that results in venous access issues and superior vena cava syndrome,
and consensus documents5,6 are based on expert opinion as to the
numbers of abandoned leads that justify extraction (a total of more
than four leads on one side or five leads through the SVC). Other
issues with abandoned leads, such as lead–lead interaction, are also
not well studied. Collection of information on how leads are aban-
doned (e.g. trans-section vs. preservation of the lead terminal con-
nector) is important since this has a bearing on future follow-up and
extraction attempts. For leads under advisory or recall, surveillance
and data collection is essential to aid with clinical decision making.23
According to the U.S. Food and Drug Administration (FDA), a recall
is an action taken to address a problem with a medical device that
violates FDA law.24 Recalls are classified by the FDA to indicate the
relative degree of health hazard presented by the product being re-
called (Table 2).25 The EU provides guidance but directives are inter-
preted by national Competent Authorities and private Notified
Bodies.26 EU member states use a different recall system to the U.S.
FDA system, namely the ‘Field Safety Corrective Action’.27 This is an
action taken by a manufacturer to reduce a risk of death or serious
deterioration in the state of health associated with the use of a
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medical device that is already placed on the market. Such actions,
whether associated with direct or indirect harm, should be reported
and should be notified via a Field Safety Notice.27,28 We recommend
the establishment of clinical registries for monitoring device and lead
performance in partnership with professional medical organizations,
healthcare, academic, and governmental organizations, such as the
FDA Manufacturer and User Facility Device Experience (MAUDE)
database. This will foster wider surveillance of lead performance and
patient outcomes in general. Standardization of terminology and data
elements is important for this process. Comprehensive surveillance
systems require key elements, such as the Unique Device
Identification (UDI) system proposed by the FDA. Creating auto-
mated tools for prospective surveillance of CIED performance may
improve the ability within a registry to detect previously unrecog-
nized safety problems. This will require coordination and integration
of information from multiple sources as proposed by the FDA and
other organizations within the Medical Device Epidemiology
Network (MDEpiNet) or similar frameworks. Finally, remote moni-
toring provides a platform from which lead (and patient) survival data
can be tracked.
Data on extraction tools
It is well accepted that the presence of a wide variety of extraction
tools is of utmost importance to guarantee maximum patient safety
as well as high procedural success rate. Comparison of safety and
efficacy of the different tools is problematic, as some devices (e.g.
snares) may be used as backup solutions for difficult cases.
Nevertheless, multicentre studies are necessary for acquiring data,
especially with the introduction of new tools for which sparse data
exist (e.g. occlusion balloons29).
Risk stratification
There are a number of risk factors associated with lead extraction
procedures. Further research may validate scores for risk-
stratification which may help with management strategies.20
Qualifications and training of operators
There continues to be a significant lack of consensus regarding how
much training should be required to become proficient in lead ex-
traction. There are guidance documents that recommend extracting
a minimum of 40 leads in at least 30 procedures as a minimal require-
ment for training, with minimum of 15 procedures (extracting at least
20 leads) each year to maintain competency.5,7 However, it is difficult
to acquire competency for the multiple available tools in performing
a limited number of cases. It has been shown in a pilot study with
eight trainees, that computer-based virtual reality training (with simu-
lation of locking stylets and laser sheaths) can provide an enhanced
learning experience, and may improve results.30 Other types of simu-
lated training are also available using anatomical models and phan-
toms, which allow measurement of parameters such as traction force
at different levels.31 Simulators may also provide a means to maintain
competency for physicians who have a low caseload. More research
is however needed to explore training pathways that can improve
learning curves and positively impact procedural outcome.
Furthermore, performing any number of cases cannot guarantee that
an operator is competent to provide safe and effective lead extrac-
tion, and currently, there are no true ‘hands on’ examinations to
evaluate competency. Virtual-reality simulators may provide metrics
that can evaluate handling of extraction tools and simulate complica-
tions,30 but their utility will be determined by the fidelity with which
they reflect the real-life setting.
Procedural volume
There is some evidence that the incidence of major complications
and death are related to the volume of a TLE centre and the individ-
ual experience of the operator.4,32–35 This volume-outcome relation-
ship is supported by data of the ELECTRa-registry,4 where the cut-off
for defining low- and high-volume centres was 30 procedures per
year. The complication rate was significantly different between low-
and high-volume centres (4.7% vs. 2.1%, respectively; P< 0.01), with
lower all-cause mortality in high-volume centres (2.8% vs. 1.2%;
P< 0.03). However, there was no significant difference in procedure-
related mortality. The LExICon-study35 differentiated between low-,
mid- and high-volume centres based on case numbers over a 4-year
period (<60, 60–130, and >130 cases). More data are required to de-
termine cut-off values that are associated with better patient out-
come, which may have future regulatory implications.
Procedural environment
The influence of different procedure rooms (catheterization or EP la-
boratory, operating room, hybrid operating room) on procedural
outcomes is a topic of potential scientific interest. In a large retro-
spective single-centre study comprising 3258 TLE procedures on the
outcomes of emergent surgical or interventional management of
major procedural complications, it was shown that mortality was sig-
nificantly higher, if emergent surgical or endovascular intervention
was performed in the EP laboratory than in an operating room
(63.6% vs. 14.3%; P= 0.01).35,36 A European Heart Rhythm
Association (EHRA) EP network survey published in 2012 revealed
that most (60%) TLE procedures at that time were performed in a
catheterization laboratory (operating room 26%, hybrid room
14%).37 In the ELECTRa registry4 52% of the procedures were per-
formed in an operating room (catheterization laboratory 38.5%, hy-
brid room 9.5%). This might reflect a shift in the safety culture of TLE
centres or might merely be related to the different participating
centres in the two data sets. Further studies addressing the issue of
complication management in TLE procedure should certainly investi-
gate the optimal environment for such procedures focusing on safety
endpoints.
Anaesthesia
A further question with lack of solid evidence is the impact of anaes-
thesia type (general anaesthesia vs. local anaesthesia with or without
sedation) on safety outcomes during TLE. Data from the ELECTRa
registry revealed an almost even distribution between three anaes-
thesia types among the participating centres with a slight trend to-
wards preferred use of general anaesthesia (general anaesthesia
38.7%, local anaesthesia 30.6%, sedation 30.7%).1 Recommendations
on TLE procedures do not clearly favour one specific anaesthesia
type, but require immediate anaesthesia support in case the proced-
ure is not performed under general anaesthesia.6,7,38 Further data
needs to be gathered and evaluated to clarify this aspect.
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Special patient populations
There exists a strong need to generate a scientific basis for future,
evidence-based lead extraction recommendations in special patient
populations. Such special patient populations consist of, but are not
restricted to paediatric, very elderly, grown-up congenital heart dis-
ease patients, and patients potentially requiring open extraction pro-
cedures (e.g. lead vegetations greater than 20 mm or leads placed
into arterial or extravascular structures). Common to all these spe-
cial patient populations is the fact that the numbers of such patients
in single institutional series, even in high volume centres, are too small
to create statistically solid data.
It is of utmost importance to perform future studies based on a
data pooling of multiple centres, either in the form of multicentre
studies or registries. Ideally, a global lead extraction registry would
pool pan-national data, but this is unlikely to happen in the foresee-
able future. In this context, a standardization of data collection should
be established to allow for complete data acquisition between mul-
tiple participating centres. As any interventional procedure requiring
individual skill, lead extraction is a difficult setting for planning a
randomized clinical trial, but questions about the gaps listed above
should minimize bias and provide appropriate answers.
Conclusions
Scientific societies have published clinical guidelines on TLE and initi-
ated large registries, which are critical to improve our understanding
in this domain. However, many questions still remain unanswered re-
garding TLE, reflecting not only the limited number of randomized tri-
als but also the lack of standards in reporting procedures and
complications. These unresolved issues have given a strong incentive
for this consensus document. The recommendations are directed to
all scientists and healthcare professionals and are pertinent to clinical
trials, registries, scientific reports, guidelines, quality assurance, and
educational programs. The document also lists numerous gaps in evi-
dence related lead extraction, with the purpose to trigger joint col-
laboration in scientific trials and registries.
Supplementary material
Supplementary material is available at Europace online.
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